Articles from Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, today announced positive topline results from Part 2 of EMBARK (Study SRP-9001-301), a global, randomized, double-blind, placebo-controlled, Phase 3 clinical study of ELEVIDYS (delandistrogene moxeparvovec-rokl), the only approved gene therapy in patients with Duchenne muscular dystrophy.

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, today reported preliminary* fourth quarter and full-year 2024 net product revenue and cash on hand as of December 31, 2024, as part of its presentation today at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, Calif.

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, Calif. on Monday, Jan. 13, 2025 at 12:00 p.m. E.T. / 9:00 a.m. P.T. Following the presentation there will be a Q&A session starting at 12:20 p.m. E.T. / 9:20 a.m. P.T.

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on December 31, 2024 (the “Grant Date”) that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 8 individuals hired by Sarepta in December 2024. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, today announced that enrollment and dosing is complete in EMERGENE (Study SRP-9003-301), a Phase 3 clinical trial of SRP-9003 (bidridistrogene xeboparvovec). SRP-9003 is an investigational gene therapy for the treatment of limb-girdle muscular dystrophy Type 2E/R4 (LGMD2E/R4), or beta-sarcoglycanopathy. EMERGENE is a global study, and the primary endpoint is the biomarker expression of beta-sarcoglycan protein, the absence of which is the sole cause of LGMD2E/R4.

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on November 29, 2024 (the “Grant Date”) that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 14 individuals hired by Sarepta in November 2024. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, today announced an exclusive global licensing and collaboration agreement with Arrowhead Pharmaceuticals, Inc. NASDAQ: ARWRNASDAQARWR)

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the third quarter 2024.

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on October 31, 2024 (the “Grant Date”) that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 15 individuals hired by Sarepta in October 2024. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2024 financial results after the Nasdaq Global Market closes on Wednesday, Nov. 6, 2024. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its third quarter 2024 financial results.

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on September 30, 2024 (the “Grant Date”) that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 28 individuals hired by Sarepta in September 2024. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, will present at the 29th Annual Congress of the World Muscle Society 2024 Congress (WMS 2024), taking place Oct. 8-12, 2024, in Prague, Czechia.

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, today announced the appointment of Deirdre P. Connelly to its Board of Directors. Ms. Connelly is a well-regarded executive with more than 30 years of experience in the pharmaceutical industry. Following Connelly’s appointment, Sarepta’s Board will comprise nine directors, eight of whom are independent.

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, today announced 25 recipients of Route 79, The Duchenne Scholarship Program for the 2024-2025 academic year. Of the academic scholarships, 20 will be awarded to individuals living with Duchenne muscular dystrophy and five to siblings of individuals living with Duchenne. Each recipient will receive a scholarship of up to $5,000.

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on August 30, 2024 (the “Grant Date”) that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 20 individuals hired by Sarepta in August 2024. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference at the New York Marriott Marquis in New York, NY. on Friday, Sept. 6, 2024, at 9:15 a.m. E.T.

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the second quarter 2024.

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on July 31, 2024 (the “Grant Date”) that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 19 individuals hired by Sarepta in July 2024. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2024 financial results after the Nasdaq Global Market closes on Wednesday, August 7, 2024. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its second quarter 2024 financial results.

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on June 28, 2024 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 23 individuals hired by Sarepta in June 2024. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, today announced U.S. Food and Drug Administration (FDA) approval of an expansion to the labeled indication for ELEVIDYS (delandistrogene moxeparvovec-rokl) to include individuals with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene who are at least 4 years of age. Confirming the functional benefits, the FDA granted traditional approval for ambulatory patients. The FDA granted accelerated approval for non-ambulatory patients. Continued approval for non-ambulatory Duchenne patients may be contingent upon verification of clinical benefit in a confirmatory trial. ELEVIDYS is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the DMD gene.

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on May 31, 2024 (the “Grant Date”) that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 9 individuals hired by Sarepta in May 2024. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, today announced that TIME named renown neuromuscular researcher, physician and gene therapy pioneer Jerry R. Mendell, M.D., to the inaugural 2024 TIME100 Health, a list of 100 individuals who most influenced global health this year. Dr. Mendell was recognized for his lifetime commitment to neuromuscular disease and achievements in genetic medicine that propelled a new age of treatment for several genetic diseases, including Duchenne muscular dystrophy.

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the first quarter 2024.

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on April 30, 2024 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 24 individuals hired by Sarepta in April 2024. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2024 financial results after the Nasdaq Global Market closes on Wednesday, May 1, 2024. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its first quarter 2024 financial results.

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on March 29, 2024 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 8 individuals hired by Sarepta in March 2024. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in fireside chats at two upcoming investor conferences:

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on Feb. 29, 2024 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 5 individuals hired by Sarepta in February 2024. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, today announced the official opening of Route 79, The Duchenne Scholarship Program for the 2024-2025 academic year. Academic scholarships of up to $5,000 will be awarded to as many as 20 individuals living with Duchenne muscular dystrophy and five siblings of individuals living with Duchenne.

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the fourth quarter and full-year 2023.

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2023 financial results after the Nasdaq Global Market closes on Wednesday, Feb. 28, 2024. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its fourth quarter and full-year 2023 financial results and to provide a corporate update.

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, today announced the U.S. Food and Drug Administration (FDA) has accepted and filed the Company's efficacy supplement to the Biologics License Application (BLA) for ELEVIDYS (delandistrogene moxeparvovec-rokl) (the “Efficacy Supplement”).

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on January 31, 2024 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 14 individuals hired by Sarepta in January 2024. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, today announced positive data from Part B of the MOMENTUM study (Study SRP-5051-201), a global, Phase 2, multi-ascending dose clinical trial of SRP-5051 (vesleteplirsen) that enrolled patients aged 8 to 21 years. SRP-5051 is a next-generation peptide phosphorodiamidate morpholino oligomer (PPMO) treatment for patients with Duchenne muscular dystrophy who are amenable to exon 51 skipping.

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, today announced that screening is underway in Study SRP-9003-301. Also known as EMERGENE, Study 9003-301 is a Phase 3, multi-national, open-label study of SRP-9003 (bidridistrogene xeboparvovec) for the treatment of limb-girdle muscular dystrophy Type 2E (LGMD2E/R4), or beta sarcoglycanopathy. EMERGENE will enroll 15 participants (ambulatory and non-ambulatory), aged 4 and older, and uses commercially representative process SRP-9003 material.

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, today reported preliminary* fourth quarter and full-year 2023 net product revenue and cash on hand as of December 31, 2023, as part of its presentation today at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, Calif.

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, Calif. on Monday, Jan. 8, 2024 at 12:00 p.m. E.T. / 9:00 a.m. P.T. Following the presentation there will be a Q&A session starting at 12:20 p.m. E.T. / 9:20 a.m. P.T.

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on December 29, 2023 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 4 individuals hired by Sarepta in December 2023. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, today announced submission of an efficacy supplement to the Biologics License Application (BLA) for ELEVIDYS (delandistrogene moxeparvovec-rokl) to expand its labeled indication as follows “[ELEVIDYS is indicated for] the treatment of Duchenne muscular dystrophy (DMD) patients with a confirmed mutation in the DMD gene.”

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on November 30, 2023 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 13 individuals hired by Sarepta in November 2023. The equity awards were approved in accordance with Nasdaq Listing Rule 5635©(4).

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the UBS Biopharma Conference on Thursday, Nov. 9, 2023 at 9:00 a.m. E.T. The fireside chat will be held at the Fontainebleau Miami Beach in Miami Beach, Fla.

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the third quarter 2023.

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on October 31, 2023 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 12 individuals hired by Sarepta in October 2023. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, today announced topline results from EMBARK (Study SRP-9001-301), a global, randomized, double-blind, placebo-controlled, Phase 3 clinical study of ELEVIDYS (delandistrogene moxeparvovec-rokl) in patients with Duchenne muscular dystrophy between the ages of 4 through 7 years.

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2023 financial results after the Nasdaq Global Market closes on Wednesday, Nov. 1, 2023. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its third quarter 2023 financial results.

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on September 29, 2023 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 24 individuals hired by Sarepta in September 2023. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, today announced 25 recipients of Route 79, The Duchenne Scholarship Program for the 2023-2024 academic year. Of the 25 recipients, academic scholarships will be awarded to 20 individuals living with Duchenne muscular dystrophy and to five siblings of individuals living with Duchenne. Each recipient will receive a scholarship of up to $5,000.

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference on Monday, Sept. 11, 2023 at 8:40 a.m. E.T. The fireside chat will be held at the Sheraton New York in New York, NY.

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on August 31, 2023 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 12 individuals hired by Sarepta in August 2023. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the second quarter 2023.

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on July 31, 2023 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 19 individuals hired by Sarepta in July 2023. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2023 financial results after the Nasdaq Global Market closes on Wednesday, August 2, 2023. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its second quarter 2023 financial results.

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, today announced it had completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV). Sarepta received a payment of $102 million upon completion of the sale.

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at Cowen's 2nd Annual RNA Therapeutics Summit on Monday, July 10, 2023 at 11:00 a.m. E.T. The fireside chat will be held virtually.

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on June 30, 2023 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 13 individuals hired by Sarepta in June 2023. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, today announced U.S. Food and Drug Administration (FDA) accelerated approval of ELEVIDYS (delandistrogene moxeparvovec-rokl), an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene. This indication is approved under accelerated approval based on expression of ELEVIDYS micro-dystrophin observed in patients treated with ELEVIDYS. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). ELEVIDYS is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the DMD gene.

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on May 31, 2023 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 33 individuals hired by Sarepta in May 2023. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, today provided the following update on the Biologics License Application (BLA) for SRP-9001 (delandistrogene moxeparvovec), which is currently under review for the treatment of ambulant individuals with Duchenne muscular dystrophy (DMD) who have a confirmed mutation of the DMD gene.

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) Cellular, Tissue and Gene Therapies Advisory Committee (CTGTAC) voted 8 to 6 in support of accelerated approval of SRP-9001 (delandistrogene moxeparvovec) for the treatment of ambulatory patients with Duchenne muscular dystrophy with a confirmed mutation in the DMD gene.

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the first quarter 2023.

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on December 31, 2022 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 18 individuals hired by Sarepta in April 2023. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2023 financial results after the Nasdaq Global Market closes on Tuesday, May 2, 2023. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its first quarter 2023 financial results.

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, today announced that the date of the U.S. Food and Drug Administration’s Cellular, Tissue and Gene Therapies Advisory Committee meeting for the SRP-9001 (delandistrogene moxeparvovec) biologics license application (BLA) is May 12, 2023. The advisory committee meeting will be hosted as a virtual meeting. SRP-9001 is Sarepta’s investigational gene therapy for the treatment of Duchenne muscular dystrophy.

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on March 31, 2023 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 18 individuals hired by Sarepta in March 2023. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, today announced that at its late cycle meeting for the SRP-9001 (delandistrogene moxeparvovec) biologics license application (BLA), the U.S. Food and Drug Administration’s Office of Therapeutics (OTP) has determined that an advisory committee meeting will be held for SRP-9001 in advance of the May 29, 2023 regulatory action date. SRP-9001 is Sarepta’s investigational gene therapy for the treatment of Duchenne muscular dystrophy.

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on February 28, 2023 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 19 individuals hired by Sarepta in February 2023. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the fourth quarter and full-year 2022.

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, today announced the official opening of Route 79, The Duchenne Scholarship Program for the 2023-2024 academic year. Academic scholarships of up to $5,000 will be awarded to up to 20 individuals living with Duchenne muscular dystrophy and up to five siblings of individuals living with Duchenne.

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full year 2022 financial results after the Nasdaq Global Market closes on Tuesday, February 28, 2023. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its fourth quarter and full-year 2022 financial results and to provide a corporate update.

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, today announced that the first patient has been dosed in Study SRP-9003-102. Also known as VOYAGENE, Study 9003-102 is a phase 1 study of SRP-9003 (bidridistrogene xeboparvovec) for the treatment of limb-girdle muscular dystrophy Type 2E/R4 (LGMD2E). VOYAGENE is a U.S.-only study enrolling ambulant patients aged 18 years or older and non-ambulant patients, ages 4-50 years, using clinical process SRP-9003 material.